Literature DB >> 20626530

Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II.

I Stoffels1, J Dissemond, A Körber, U Hillen, T Poeppel, D Schadendorf, J Klode.   

Abstract

BACKGROUND: Sentinel lymph node excision (SLNE) for the detection of regional nodal metastases and staging of malignant melanoma has resulted in some controversies in international discussions, as it is a cost-intensive surgical intervention with potentially significant morbidity.
OBJECTIVE: The present retrospective study seeks to clarify the effectiveness and reliability of SLNE performed under tumescent local anaesthesia (TLA) and whether SLNE performed under TLA can reduce costs and morbidity. Therefore, our study is a comparison of SLNE performed under TLA and general anaesthesia (GA). PATIENTS: We retrospectively analysed data from 300 patients with primary malignant melanoma with a Breslow index of ≥1.0 mm.
RESULTS: Altogether, 211 (70.3%) patients underwent SLNE under TLA and 89 (29.7%) patients underwent SLNE under GA. A total of 637 sentinel lymph nodes (SLN) were removed. In the TLA group 1.98 SLN/patient and in the GA group 2.46 SLN/patient were removed (median value). Seventy patients (23.3%) had a positive SLN. No major complications occurred. The costs for SLNE were significantly less for the SLNE in a procedures room performed under TLA (mean € 30.64) compared with SLNE in an operating room under GA (mean € 326.14, P<0.0001).
CONCLUSION: In conclusion, SLNE performed under TLA is safe, reliable, and cost-efficient and could become the new gold standard in sentinel lymph node diagnostic procedures.
© 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 20626530     DOI: 10.1111/j.1468-3083.2010.03786.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma.

Authors:  Ingo Stoffels; Markus Müller; Marie Henrike Geisel; Julia Leyh; Thorsten Pöppel; Dirk Schadendorf; Joachim Klode
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-25       Impact factor: 9.236

2.  Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Authors:  Benedikt Michael Schaarschmidt; Johannes Grueneisen; Vanessa Stebner; Joachim Klode; Ingo Stoffels; Lale Umutlu; Dirk Schadendorf; Philipp Heusch; Gerald Antoch; Thorsten Dirk Pöppel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

3.  Histological Surprises in Benign Cytologies after Lymph Node Biopsy-Surgeon's Knife Improving Patient Care.

Authors:  Mario Victor Newton; Rakesh S Ramesh; Suraj Manjunath; K ShivaKumar; Hemanth G Nanjappa; Ramu Damuluri; Elvis Peter Joseph; C Prasad
Journal:  Indian J Surg Oncol       Date:  2016-11-29

4.  Acral, Superficial Spreading Melanoma Arising on Melanocytic Nevus in a Pregnant Woman: A Case Report with Review.

Authors:  Sunil Kumar Gupta; Ajay Kumar; Vivek Gupta; Alpna Thakur
Journal:  Indian J Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.494

5.  Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement.

Authors:  Eric A Deckers; Marieke Wj Louwman; Schelto Kruijff; Harald J Hoekstra
Journal:  Melanoma Manag       Date:  2020-03-30

6.  Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia: a prospective study.

Authors:  Philipp Jansen; Ingo Stoffels; Anne-Christine Müseler; Maximilian Petri; Titus J Brinker; Manfred Schedlowski; Dirk Schadendorf; Harald Engler; Joachim Klode
Journal:  World J Surg Oncol       Date:  2020-03-10       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.